PubMed

Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.

Currier JS, Williams PL, Koletar SL, Cohn SE, Murphy RL, Heald AE, Hafner R, Bassily EL, Lederman HM, Knirsch C, Benson CA, Valdez H, Aberg JA, McCutchan JA.

Ann Intern Med. 2000 Oct 3;133(7):493-503.PMID: 11015162 [PubMed - indexed for MEDLINE]Related articlesFree article

Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS.

El-Sadr WM, Burman WJ, Grant LB, Matts JP, Hafner R, Crane L, Zeh D, Gallagher B, Mannheimer SB, Martinez A, Gordin F.

N Engl J Med. 2000 Apr 13;342(15):1085-92.PMID: 10766581 [PubMed - indexed for MEDLINE]Related articlesFree article

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group.

Havlir DV, Dubé MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Lavelle JP, White AC Jr, Witt MD, Bozzette SA, McCutchan JA.

N Engl J Med. 1996 Aug 8;335(6):392-8.PMID: 8676932 [PubMed - indexed for MEDLINE]Related articlesFree article

Disseminated M. avium complex infection in the Swiss HIV Cohort Study: declining incidence, improved prognosis and discontinuation of maintenance therapy.

Rossi M, Flepp M, Telenti A, Schiffer V, Egloff N, Bucher H, Vernazza P, Bernasconi E, Weber R, Rickenbach M, Furrer H; Swiss HIV Cohort Study.

Swiss Med Wkly. 2001 Aug 11;131(31-32):471-7.PMID: 11641970 [PubMed - indexed for MEDLINE]Related articlesFree article

Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial.

Oldfield EC 3rd, Fessel WJ, Dunne MW, Dickinson G, Wallace MR, Byrne W, Chung R, Wagner KF, Paparello SF, Craig DB, Melcher G, Zajdowicz M, Williams RF, Kelly JW, Zelasky M, Heifets LB, Berman JD.

Clin Infect Dis. 1998 Mar;26(3):611-9.PMID: 9524832 [PubMed - indexed for MEDLINE]Related articles

AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A.

JAMA. 1999 Dec 15;282(23):2220-6.PMID: 10605973 [PubMed - indexed for MEDLINE]Related articlesFree article

Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study.

Furrer H, Telenti A, Rossi M, Ledergerber B.

AIDS. 2000 Jul 7;14(10):1409-12.PMID: 10930156 [PubMed - indexed for MEDLINE]Related articles

Presence of macrolide resistance in respiratory flora of HIV-Infected patients receiving either clarithromycin or azithromycin for Mycobacterium avium complex prophylaxis.

Aberg JA, Wong MK, Flamm R, Notario GF, Jacobson MA.

HIV Clin Trials. 2001 Nov-Dec;2(6):453-9.PMID: 11742432 [PubMed - indexed for MEDLINE]Related articlesFree article

Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy.

Shafran SD, Mashinter LD, Phillips P, Lalonde RG, Gill MJ, Walmsley SL, Toma E, Conway B, Fong IW, Rachlis AR, Williams KE, Garber GE, Schlech WF, Smaill F, Pradier C.

Ann Intern Med. 2002 Nov 5;137(9):734-7.PMID: 12416943 [PubMed - indexed for MEDLINE]Related articlesFree article

A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.

Lopez Bernaldo de Quiros JC, Miro JM, Peña JM, Podzamczer D, Alberdi JC, Martínez E, Cosin J, Claramonte X, Gonzalez J, Domingo P, Casado JL, Ribera E; Grupo de Estudio del SIDA 04/98.

N Engl J Med. 2001 Jan 18;344(3):159-67.PMID: 11172138 [PubMed - indexed for MEDLINE]Related articlesFree article

A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome.

Pierce M, Crampton S, Henry D, Heifets L, LaMarca A, Montecalvo M, Wormser GP, Jablonowski H, Jemsek J, Cynamon M, Yangco BG, Notario G, Craft JC.

N Engl J Med. 1996 Aug 8;335(6):384-91.PMID: 8663871 [PubMed - indexed for MEDLINE]Related articlesFree article

Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study.

Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, Katzenstein T, van Lunzen J, Antunes F, Phillips AN, Lundgren JD.

Ann Intern Med. 1999 Apr 6;130(7):570-7.PMID: 10189326 [PubMed - indexed for MEDLINE]Related articlesFree article

Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis.

Bayoumi AM, Redelmeier DA.

AIDS. 1998 Aug 20;12(12):1503-12.PMID: 9727572 [PubMed - indexed for MEDLINE]Related articles

Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program.

Phillips P, Chan K, Hogg R, Bessuille E, Black W, Talbot J, O'Shaughnessy M, Montaner J.

Clin Infect Dis. 2002 Feb 1;34(3):371-8. Epub 2001 Dec 14.PMID: 11774085 [PubMed - indexed for MEDLINE]Related articles

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM.

Ann Intern Med. 2001 Dec 4;135(11):954-64.PMID: 11730396 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group.

Angel JB, High K, Rhame F, Brand D, Whitmore JB, Agosti JM, Gilbert MJ, Deresinski S.

AIDS. 2000 Mar 10;14(4):387-95.PMID: 10770541 [PubMed - indexed for MEDLINE]Related articles

Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy.

Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gerstoft J, Pradier C, Wit FW, Ledergerber B, Lundgren JD, Furrer H; European HIV Cohorts.

Ann Intern Med. 2002 Aug 20;137(4):239-50.PMID: 12186514 [PubMed - indexed for MEDLINE]Related articlesFree article

Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.

SMART Study Group, El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD.

Ann Intern Med. 2008 Sep 2;149(5):289-99.PMID: 18765698 [PubMed - indexed for MEDLINE]Related articlesFree article

Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections.

Williams PL, Currier JS, Swindells S.

AIDS. 1999 Jun 18;13(9):1035-44.PMID: 10397533 [PubMed - indexed for MEDLINE]Related articles

The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.

Montaner JS, DeMasi R, Hill AM.

AIDS. 1998 Mar 26;12(5):F23-8.PMID: 9543436 [PubMed - indexed for MEDLINE]Related articles